无创治疗

Search documents
中惠医疗:以无创科技构建“大健康”新生态
Zheng Quan Ri Bao Wang· 2025-09-19 06:46
Group 1 - The core viewpoint of the article emphasizes that Zhonghui Medical is leveraging non-invasive ultrasound technology to build a new "big health" ecosystem in China, positioning itself as a leader in this field through original research and development [1][2] - The company has made significant advancements over the past decade, evolving its technology from a high-intensity focused ultrasound tumor treatment system to a dual-energy ultrasound treatment robot, which is expected to be used for non-invasive breast tumor treatment by 2027 [1][2] - Zhonghui Medical is not just a device manufacturer but is also focused on implementing non-invasive concepts and ecosystems, utilizing cutting-edge technology combined with remote collaboration to enhance healthcare accessibility [2] Group 2 - The company has established partnerships with over 20 top-tier hospitals and several universities, working on integrated "production, learning, research, and application" to overcome industry bottlenecks and ensure regulatory compliance [2] - Current products are covered by medical insurance, allowing patients to pay only 20%-30% of the costs for treatments related to liver cancer and uterine fibroids, thus democratizing access to advanced medical technologies [2] - Zhonghui Medical is expanding its non-invasive ultrasound ecosystem into pet healthcare and aesthetic medicine, with commercialized products already in major cities and ongoing clinical research collaborations [2] Group 3 - The company is accelerating its international expansion under the "Belt and Road" initiative, aiming to establish "Chinese standards" in the global non-invasive medical market while pursuing EU certification [2][3] - Challenges include the need for continuous clinical data accumulation and grassroots market education, but the company remains committed to deepening its focus on non-invasive technologies and promoting quality healthcare resources [3] - With rapid technological advancements and market support, Zhonghui Medical is transitioning from an "industry innovator" to a "global leader," showcasing the strength of Chinese medical innovation [3]
中国原创大型医疗设备“海扶刀”首进乌拉圭
Zhong Guo Xin Wen Wang· 2025-06-10 15:29
Core Viewpoint - The export of the HaiFu Knife® focused ultrasound tumor treatment system to Uruguay marks the expansion of this Chinese original large medical device to 34 countries and regions globally [1][2] Group 1: Product and Technology - The HaiFu Knife is designed for the treatment of various benign and malignant tumors, including uterine fibroids, adenomyosis, breast fibroadenomas, liver cancer, pancreatic cancer, and breast cancer [1] - Its core technology utilizes focused ultrasound to precisely target lesions within the body, achieving non-invasive treatment through mechanical, thermal, and cavitation effects, leading to irreversible coagulative necrosis of the lesions [1] - The technology is particularly beneficial in gynecological diseases, preserving the structure and function of organs, thus protecting women's fertility [1] Group 2: Market Expansion and Impact - The shipment to Uruguay represents the seventh HaiFu Knife in Latin America, with previous installations in Mexico, Cuba, Dominica, Venezuela, Colombia, and Argentina [1] - The establishment of the first HaiFu Center in Uruguay is expected to provide patients with access to internationally leading treatment technology [1][2] - The growth potential for the application of the HaiFu Knife in Latin America is significant, with expectations for safer and less invasive treatment options for patients [2] Group 3: Training and Development - Sixteen Uruguayan doctors and management personnel participated in a two-week professional training program in China, covering various medical fields including obstetrics, urology, surgery, oncology, and cardiology [2] - The goal of the training is to provide more treatment options for patients with benign and malignant tumors [2] Group 4: Global Impact - As of the end of 2024, the HaiFu Knife has treated over 320,000 patients with benign and malignant tumors worldwide [2]